Navigation Links
Low glycemic diet effective for reducing cardiovascular risk,,

Researchers from Children's Hospital, Boston, US, have reported that a diet// with low glycemic load will be much beneficial for people suffering from cardiovascular disease than the conventional low fat diet.

A Glycemic index measures how the food affects our blood sugar. Glycemic Index (GI) ranks foods on their effect on the blood sugar level. The index ranges from 1 to 100. Some food items raise the blood glucose level more than the others. These are the ones with low GI (less than 55). High GI foods usually rate more than 70.

The study had 23 obese adults have any one of the two types of diets; the first one was with foods of low GI without any strict restriction on fat or carbohydrate. The control diet plan was restricted intake of carbohydrates and fat.

The results of the study showed decrease in body weight significantly after being on the former diet for six months. There was also a decline in plasma triacylglycerols in the first type of diet than the conventional low fat, low carbohydrate diet. The research shows that food with low glycemic load may benefit the cardiac patients by lowering their cardiovascular risk.
'"/>




Page: 1

Related medicine news :

1. Breast cancer is associated to consuming food with high glycemic index
2. Link found between depression and poor glycemic control
3. Glucommander: A safe and simple method of glycemic control
4. Glucose Causes Death of Brain Cells in Rodents Following Hypoglycemic Coma
5. Morning after pill effective up to five days after having unprotected sex
6. Distraction therapy found very effective in postoperative patients
7. TELITHROMYCIN - the proven effective new drug for cap
8. Digital mammography proves effective
9. Treatment for pre-menstrual syndrome is ineffective
10. Cost-effective antibiotics for sinusitis treatment
11. An effective way to treat angina
Post Your Comments:
(Date:7/25/2008)...e/ -- Klafter & Olsen LLP has filed a,class action...re" or the,"Company") (Nasdaq: ARTC ) and certain...e Western District of Texas on behalf of all perso...roCare from January 24, 2008,through July 18, 2008...ll,persons or entities who purchased call options ...
(Date:7/25/2008)...iretroviral therapy may be due to genetic factors ...A new study challenges the long-held belief that t...em,s ability to restore itself after HIV patients ...apy (HAART). , From 50 percent to 90 percent of...V. Intravenous drug use is the main cause of both ...
(Date:7/25/2008)...- BeaconEquity.com announces the,availability of T...rs can view all of the daily trading notes for fre...,s Trade Alerts include: DUSA Pharmaceuticals Inc..... (Nasdaq: MBRK ), NovaMed Inc. (Nasdaq:,NOVA), A...daq: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., J...
(Date:7/25/2008)...gnificant Improvements in Members, Health, ATLANT...er in health,care quality management solutions for...s entered into a long-term agreement with Wellmark...tion on Quality(SM) Incent and,Reward Best Practic...d,primary care clinicians to promote improved qual...
Breaking Medicine News(10 mins):Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3
...Radiologists are enabled to get more detailed imag...advances made in CT scanners, which also serves to... undergo. // Back in 1987, patients had to undergo...table angiograms before going for a bypass surgery...
...Newer antibiotics like cephalosporins will replace...ing ailments like strep throat, as they are seen t...atment given to // 11,426 children, showed that ev...s more effective than the traditional 10-day dose ...
...A new research has revealed that happiness results...hological Bulletin of the American Psychological A...tributes towards // reinforcing positive emotions,...ake new goals and succeed at them. Dr. Sonja Lyu...
...People in general tend to get the blues during the...they recover soon enough. It is far more difficult..., and the people who suffer // from it require hel..., sleep a lot, and tend to put on weight. They exp...
Other Medicine News:Health News:Penicillin To Pave Way For New Antibiotics 2Health News:Happiness Plays An Important Role In Success 2
(Date:7/22/2008)...July 22 /- Following a,thor...rd of Progen,Pharmaceuticals Limited (ASX: PGL; Na...ed the PI-88 phase 3 study in liver cancer. Progen...existing portfolio of compounds and,the company wi...nd,opportunities through Merger & Acquisition acti...
(Date:7/22/2008)...herapeutics Development Initiative bring MJFF,s,cu...eadline January 20,2009, NEW YORK, July 22 /PRNe...eed delivery of transformative treatments and a cu...ndation for Parkinson,s Research has awarded,$2.7 ...teams. The awards,were granted under MJFF,s Therap...
(Date:7/22/2008)...tudy Confirms Tyrima Exhibits Excellent Drug-Like ...Results Support Initiation of Phase II Clinical Tr...Newswire/ -- CeNeRx BioPharma,Inc., a clinical st...ive,treatments for diseases of the central nervous... candidate Tyrima(TM) into Phase II trials for the...
(Date:7/22/2008)...Calif., July 22 /- Hyperion,Therapeut...tient enrollment,in its Phase 1/2 clinical trial t...avenging effects of HPN-100 (formally called GT4P)...ients with urea cycle disorders,(UCD). The company...quarter,of this year., (Logo: http://www.newscom...
Breaking Medicine Technology:Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3Many African Americans have a gene that prolongs life after heart failure 2966 1Many African Americans have a gene that prolongs life after heart failure 2966 2Many African Americans have a gene that prolongs life after heart failure 2966 3Many African Americans have a gene that prolongs life after heart failure 2966 4Allergies Can Dig Into Gardenings Fun 17255 1Allergies Can Dig Into Gardenings Fun 17255 2BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance 4712 1BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance 4712 2BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance 4712 3Angiotechs Corporate Partner Boston Scientific Reports Canadian Approval for TAXUS 28R 29 Liberte 28R 29 Stent System 4710 1Angiotechs Corporate Partner Boston Scientific Reports Canadian Approval for TAXUS 28R 29 Liberte 28R 29 Stent System 4710 2Angiotechs Corporate Partner Boston Scientific Reports Canadian Approval for TAXUS 28R 29 Liberte 28R 29 Stent System 4710 3Angiotechs Corporate Partner Boston Scientific Reports Canadian Approval for TAXUS 28R 29 Liberte 28R 29 Stent System 4710 4
...BRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - AVE...ny focused on the,discovery and development of nov...t it will present a total of 12 oral and poster,pr... Research,(AACR) Annual Meeting on April 14-18, 20...ted to share with the cancer community the,pioneer...
...NDON, April 12, 2007--The costs of eradicating,pol...while high in,the short term, are much lower than ...s without eradication. And a recently developed,mo...ive against,type 1 poliomyelitis than an existing ...rticles published Online and in an upcoming,issue ...
Other Medicine Technology:AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical,Pipeline to Be Featured at AACR 2AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical,Pipeline to Be Featured at AACR 3Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 2Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 3
Angled for temporal approach. Solid 14 mm blades. Dull finish.
Solid 8 mm blades. Dull finish. Most popular size or model.
Closed wire 5 mm blade with a wing tip twist giving the surgeon better on-axis accessibility.
Angled for temporal approach. Wire 14 mm rounded blades for patient comfort. Dull finish.
Medicine Products: